The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker Abciximab: ReoProR Coated Stent in Patients with Coronary Artery Disease

Abstract

Background :Previously, the inhibition of coronary restenosis with Abciximab (ReoPro®)-coated stent in a porcine model was reported. ReoPro® inhibits platelet aggregation, the proliferation of vascular smooth muscle cells and the inflammatory reaction.Methods :A prospective randomized trial was performed to compare two types of stent for revascularization in the native coronary artery. The primary effective end points were major adverse coronary events (MACE): cardiac death, acute myocardial infarction, target vessel revascularization (TVR) and restenosis at the 6-month clinical and angiographic follow-ups.Results :One hundred and fifty-five patients were enrolled between August 2001 and June 2003. The mean ages (56.0±10.0 vs. 56.9±10.8 years), baseline diameter of stenosis and minimal luminal diameter were no different between the two groups. There was one myocardial infarction and revascularization during the hospital stay in control stent group. During the clinical follow-up there were two myocardial infarctions in control group. Follow-up coronary angiograms were performed in 62.3% (48/77) and 65.4% (51/78) of the coated and control groups, respectively. The diameter of stenosis and late loss were significantly less in the ReoPro®-coated stent group compared with the controls (16.4±5.8% vs. 34.3±6.1%, p=0.009; and 0.33±0.28 mm vs. 0.88±0.41 mm; p=0.002). The restenosis and TVR rates of the ReoPro®-coated stent were relatively lower compared with the control stent [14.6% (7/48) vs. 29.4% (15/51), p=0.062; and 9.2% (7/76) vs. 14.7% (11/75); p=0.327].Conclusion :A ReoPro®-coated stent is safe, and may be effective in the prevention of coronary restenosis.

In‐vitro assays of polymer‐coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody

“…Blockade of platelet GP IIb/IIIa receptor by monoclonal antibodies inhibits platelet aggregation and protects against thrombosis and ischemic damage. Clinically, the systemic use of c7E3 (ReoPro, abciximab) has been shown to significantly reduce the thrombotic complications following complex angioplasty and stenting 15–20…”

A Bumpy and Winding but Right Path to Domestic Drug-Eluting Coronary Stents

“… 5) In a study of 150 patients, the restenosis and target-vessel restenosis rates of an abciximab-coated stent were lower than those with a conventional BMS. 72) Later, in a study of 96 patients, follow-up IVUS demonstrated an improved intrastent luminal area and intrastent NIH. The ISR rate was lower in the abciximab-coated stent group than in the conventional BMS group.…”

Role of Integrins in Modulating Smooth Muscle Cell Plasticity and Vascular Remodeling: From Expression to Therapeutic Implications

“…Therefore, clinical trials specifically designed to assess the long-term effect of integrin-blocking on clinical restenosis are required. Another study tested the safety and efficacy of abciximab-coated stents in native human coronary artery lesions [ 102 ]. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group than in the control stent group, which indicated abciximab-coated stents to be safe and effective in the prevention of coronary restenosis [ 103 ].…”